A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Attune Medical

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical products and solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency (RF) cardiac ablation procedures.

Terms of Agreement

Under the terms of the agreement, Haemonetics will acquire Attune Medical for an upfront cash payment of $160 million at closing plus additional contingent consideration based on sales growth in the three years following the consummation of the transaction and the achievement of certain other milestones. The acquisition is subject to customary closing conditions and is expected to be completed in the first quarter of Haemonetics’ fiscal year 2025.

ensoETM

In the treatment of atrial fibrillation, a condition that affects 3 to 6 million people in the U.S., ensoETM significantly reduces the likelihood of esophageal injury during RF cardiac ablations. Additionally, studies have reported reduced procedure times and patient readmissions, and increased rates of same-day discharge and long-term procedure success with the use of ensoETM.

Stewart Strong, Haemonetics’ President, Global Hospital

“Attune Medical’s ensoETM will bolster Haemonetics’ presence in the electrophysiology market and complement our leadership in Vascular Closure. EnsoETM effectively reduces esophageal injuries without requiring hospitals to purchase complex and costly new ablation systems. With this groundbreaking solution we look forward to empowering more physicians to improve patient outcomes, and expanding our EP portfolio with yet another industry-leading technology to accelerate the growth and impact of our Interventional Technologies business.”

Jay Istvan, Chief Executive Officer at Attune Medical

“We are thrilled to become part of Haemonetics. Their Hospital business has strong positions in both EP and critical care, and their international channels are robust and expanding. We believe Haemonetics is the best company to bring ensoETM’s substantial benefits to more caregivers worldwide to enable new standards of care.”

Attune Medical generated approximately $22 million in revenue during its most recently completed fiscal year ended December 31, 2023, more than doubling its revenue from the prior fiscal year. Haemonetics expects this transaction to be immediately accretive to revenue and earnings growth following the completion of the transaction.

Haemonetics plans to finance this acquisition through a combination of cash-on-hand and a draw under its revolving credit facility.

DLA Piper served as legal advisor for Haemonetics. William Blair served as financial advisor and Perkins Coie served as legal advisor for Attune Medical.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.
“The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions,” said Adam Mumford, Director of Medical Devices at Owen Mumford. “By combining Owen Mumford's global expertise with Empelvic's innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”
"The acquisition of Beyond HME represents a pivotal moment for ACU-Serve as we continue to pursue strategic growth opportunities in the healthcare sector," said Jim Knight, President of ACU-Serve. "Beyond HME's reputation for excellence and its focus on re-supply services complement our existing offerings, positioning us for even greater success in meeting the evolving needs of our clients."
Avant Technologies CEO Timothy Lantz: “We are excited about this opportunity to accelerate Avant’s growth within the healthcare sector and create new value for our customers and shareholders. This acquisition will serve to further strengthen our financial position, unlock new growth opportunities in one of the top segments of AI adoption, and bolster our internal product development and client services capabilities.”
"Thanks to the nature of software, our platform can distribute new, advanced and validated digital diagnostics to the market globally with unprecedented speed," said Linus Health CEO and Co-Founder David Bates, PhD. "As with any chronic illness, earlier detection of brain-related disabilities allows for intervention that can delay, modify or even prevent progression of the disease. It's why we are engineering the most inclusive approach to assessing and monitoring brain function, one that includes speech and movement, in addition to memory and other neurological functions."

By using this website you agree to accept Medical Device News Magazine Privacy Policy